Head & Neck Cancers | Clinical

Phase 2 INSPIRE Trial of IRX-2 Misses EFS End Point in Head and Neck Cancer

July 28, 2022

IRX-2 did not demonstrate a statistically significant improvement in event-free survival as neoadjuvant therapy vs standard of care in patients with newly diagnosed, stage II, III, or IVA squamous cell carcinoma of the oral cavity, according to data from the phase 2 INSPIRE trial.

KEYNOTE-412 Fails to Show EFS Advantage in Unresected Locally Advanced HNSCC

July 20, 2022

Patients with unresected locally advanced head and neck squamous cell carcinoma did not show a significant improvement in event-free survival when treated with pembrolizumab and concurrent chemoradiation followed by pembrolizumab maintenance in the phase 3 KEYNOTE-412 study.

HPV16+ HNSCC Response to PDS0101 Plus Pembrolizumab in VERSATILE-002

June 08, 2022

In CPI-naïve, HPV16-positive, CPS-positive patients, PDS0101 plus pembrolizumab exhibits preliminary evidence of clinical benefit in a majority of patients with an acceptable safety profile and allows continued dosing of pembrolizumab.